Teva seeks venture partner in Japan

Fresh off its $7.5 billion deal to buy Barr Pharmaceuticals, Teva is eyeing joint ventures in Japan. CEO Shlomo Yanai told the Financial Times that establishing a beachhead in that country is a top priority for him. Though Japan has historically stuck mostly to brand-name meds, partly because of quality concerns, Yanai believes that Teva's rep can overcome that reticence. "Right now Japan is more ripe for generics," he told the newspaper. "Japan is very important but difficult to break into."

Hence the desire for a joint venture, which would give Teva a foot in the door. That's not the only option, Yanai says, but it's "definitely the preferred option."

- see the Financial Times article

Relate darticles:
It's Teva plus Barr in a $7.46B buyout
Teva Pharmaceutical - best Pharma Stocks of 2007
Teva earmarks $1B for India

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.